Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that Nicole Hayes, a senior communications leader, is joining the company as Director of U.S. External Communications responsible primarily for Media Relations. Hayes, who officially joined Bayer yesterday, brings extensive agency and corporate communications and brand storytelling experience to Bayer. In her new role, Hayes will develop and drive an integrated strategy that leverages a compelling narrative, executive visibility and thought

Bayer Hires Nicole Hayes as Director of U.S. External Communications

BWX Technologies

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com Trending

BWXT Medical, Bayer AG Ink Agreement On Actinium-225

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The seven recipients will receive a combined total of $1 million in grants over a two-year period, making the PHAB Awards one of the largest i

Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new investigational data from its established portfolio of approved oncology therapies at the upcoming ESMO Congress 2021 from September 16-21, 2021. Presentations will center around Bayer's ongoing focus in addressing patient needs through expanded research with existing therapies in certain cancers, as well as studies in new tumor types and in combination with other therapies. Among the featured research presented will be three subset analys

Bayer to Highlight Expanded Research from Growing Oncology Portfolio at ESMO Congress 2021

Bayer (BAYRY) posts positive data from the phase IIb PAGANINI study which is evaluating its investigational candidate, eliapixant, in patients with refractory chronic cough.

Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy Goal

Amazon

Aspen Technology Inc

Alibaba

Baidu

British American Tobacco

Anheuser-Busch InBev

Campbell Soup

Enterprise Products Partners

GlaxoSmithKline

Imperial Brands PLC

Intel

Kellogg

Lockheed Martin

Merck

Polaris

Reckitt Benckiser Group PLC

Roche Holding AG

Sanofi

Tencent Holdings Limited

Western Union

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The September 2021 Heat Map

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in women's healthcare, announced today that it started the Phase III clinical development program OASIS, which aims to evaluate the efficacy and safety of the investigational compound, elinzanetant for the treatment of vasomotor symptoms during menopause. elinzanetant is currently under development as a potential non-hormonal, once-daily, oral, dual neurokinin-1,3 receptor antagonist. In September 2020, Bayer completed the acquisition of K

Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that detailed results from the Phase III FIGARO-DKD study demonstrated that compared with placebo, KERENDIA® (finerenone) – a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA)3,4 – significantly reduced the risk of the composite primary endpoint of time to first occurrence of cardiovascular (CV) death or nonfatal CV events (myocardial infarction, stroke or heart failure hospitalization) by 13% (relative risk reduction,

Bayer Announces KERENDIA® (finerenone) Reduces the Risk of Cardiovascular Outcomes in New Phase III FIGARO-DKD Study in Adults With Chronic Kidney Disease (Stages 1-4) Associated With Type 2 Diabetes

Bayer is still in a downtrend with the legal battle going on and a settlement still unclear.

Bayer: Still A Bargain Despite Ongoing Legal Challenges

Bayer on Monday said it filed a petition with the U.S. Supreme Court to reverse court verdicts that awarded damages to a customer blaming his cancer on use of the German group's glyphosate-based weedkillers.

Bayer takes legal battle over glyphosate cancer claims to U.S. supreme court

LEVERKUSEN, Germany--(BUSINESS WIRE)--Today Bayer – through its subsidiary Monsanto – filed its Petition for a Writ of Certiorari with the U.S. Supreme Court in Hardeman, the only Roundup™ federal product liability case to have gone to trial. The Petition urges the Court to review the Ninth Circuit Court of Appeals' decision on two grounds. First, the state-law failure-to-warn claims at the center of the case are preempted by federal law, as the U.S. Government argued in its amicus filing in th

Bayer Announces Filing of Petition to U.S. Supreme Court for Review of Hardeman Decision

Berkeley Lights, Inc.

Berkeley Lights Inc (NASDAQ: BLI) reports Q2 sales of $19.3 million, +82% Y/Y, but slightly missing the consensus of $19.64 million. The Company expanded the installed base to 92 platforms, with seven new direct placements shipped in the quarter.

Berkeley Lights, Bayer Ink Discovery Pact For Next-Gen Traits In Agricultural Sector, Berkeley Q2 Earnings Miss Estimates

Eli Lilly

Pfizer

These stocks offer solid growth opportunities.

3 Pharma Stocks to Buy in August

Bayer lost a third appeal against U.S. court verdicts that awarded damages to customers blaming their cancers on use of its glyphosate-based weedkillers, leaving the German drugs and pesticides group to pin hopes for legal relief on the U.S. Supreme Court.

Bayer loses third appeals case over glyphosate weedkiller

Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2021.

Bayer's (BAYRY) Q2 Earnings & Revenues Surpass Estimates

Werner Enterprises

Bayer's (BAYZF) CEO Werner Baumann on Q2 2021 Results - Earnings Call Transcript

BERLIN--(BUSINESS WIRE)--Bayer AG today announced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics. Vividion's platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. Vividion's lead programs include multiple precision oncol

Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics

New medicines target an aging yet increasingly well-off country

Bayer Sees A Golden Age For China's Pharmaceutical Market

Bayer lifts 2021 view as second-quarter loss narrows

Apple

AbbVie

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Apollo Investment

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Preferred Apartment Communities

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Boeing

Bank of America

BASF SE

Brookfield Renewable Partners

B&G Foods

Brookfield Infrastructure Partners L.P.

Bayerische Motoren Werke AG

My Dividend Portfolio: July 2021 Update - 99 Holdings, 35 Buys, Dividend Record

Bayer on Thursday lifted its outlook for 2021, citing double digit growth rates at all divisions during the second-quarter, most notably its pharmaceuticals unit.

Bayer raises outlook after strong Q2

Bayer on Thursday said it acquired U.S.-based biopharmaceuticals company Vividion Therapeutics for up to $2 billion to boost its ability to discover new treatments and lift the value of its drug pipeline.

Bayer buys biopharma firm Vividion Therapeutics for up to $2 billion

Bayer to acquire Vividion Therapeutics in a $2 billion deal

Germany's Bayer said on Thursday that it would post an additional provision of $4.5 billion related to litigation of its Roundup weedkiller.

Bayer posts additional $4.5 billion provision for Roundup litigation

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer today provided an update on its five-point plan to address future Roundup™ litigation risk after its May 27th decision to withdraw from the national class process. The company is now in more control of important aspects of the risk mitigation process and has sketched out two basic scenarios going forward to provide a path to closure of this litigation. The first scenario is based on obtaining a favorable decision by the United States Supreme Court on

Bayer Provides Update on Path to Closure of Roundup™ Litigation

News for Bayer AG Stock (BAYRY)